Published in Am J Kidney Dis on October 01, 2003
Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol (2006) 1.28
Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ (2005) 1.26
The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol (2006) 1.16
Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol (2007) 1.15
Acute renal dysfunction in liver diseases. World J Gastroenterol (2007) 1.15
Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology (2015) 1.10
Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol (2005) 1.06
Sickle cell nephropathy: challenging the conventional wisdom. Pediatr Nephrol (2011) 0.99
Hepatitis B and C in dialysis units in Kosova. Virol J (2009) 0.99
Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis (2009) 0.95
Chronic hepatitis C. Gut Liver (2011) 0.94
Hepatitis C virus associated glomerulopathies. World J Gastroenterol (2014) 0.92
Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol (N Y) (2012) 0.92
Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol (2006) 0.91
Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan. BMC Nephrol (2013) 0.90
Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One (2014) 0.90
Infections in hemodialysis: a concise review. Part II: blood transmitted viral infections. Hippokratia (2011) 0.90
Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. Eur J Cancer Prev (2011) 0.89
Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin J Am Soc Nephrol (2008) 0.89
Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis. PLoS One (2014) 0.86
Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat Mon (2010) 0.85
Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol (2008) 0.85
Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother (2013) 0.83
Chapter 9: Infection-related glomerulonephritis. Kidney Int Suppl (2011) (2012) 0.82
Profile of hepatitis B virus, hepatitis C virus, hepatitis d virus and human immunodeficiency virus infections in hemodialysis patients of a tertiary care hospital in uttarakhand. J Clin Exp Hepatol (2013) 0.82
Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep (2015) 0.82
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond) (2015) 0.82
Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C. J Gastroenterol (2009) 0.80
Treatment of HCV patients before and after renal transplantation. Hepat Mon (2011) 0.80
Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. Dig Dis Sci (2015) 0.80
Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C. BMC Nephrol (2012) 0.79
Hepatitis C infection in hemodialysis patients: A review. World J Hepatol (2015) 0.79
Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey. J Gastroenterol (2009) 0.79
Effect of dialysis modality on survival of hepatitis C-infected ESRF patients. Clin J Am Soc Nephrol (2011) 0.78
Effects of pegylated interferon alpha-2a on hepatitis-C-virus-associated glomerulonephritis. Pediatr Nephrol (2008) 0.78
Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil. Virol J (2013) 0.78
Hepatitis C and kidney transplantation. Int J Nephrol (2011) 0.77
Differential Effect of Viral Hepatitis Infection on Mortality among Korean Maintenance Dialysis Patients: A Prospective Multicenter Cohort Study. PLoS One (2015) 0.77
Management of the kidney transplant patient with chronic hepatitis C infection. Int J Nephrol (2011) 0.76
HIV-associated immune complex kidney disease. Nat Rev Nephrol (2016) 0.76
Kidney transplantation from donors with hepatitis C infection. World J Gastroenterol (2014) 0.76
Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C. Clin Exp Nephrol (2012) 0.76
A study of the immunoloregulation of double filtration plasmapheresis in maintenance hemodialysis patients with chronic hepatitis C. PLoS One (2013) 0.75
Conservative Management of Chronic Renal Failure. Med J Armed Forces India (2011) 0.75
Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature. Oncotarget (2017) 0.75
Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol (2006) 0.75
Vasculitic syndromes in hepatitis C virus: A review. J Adv Res (2016) 0.75
Diabetes mellitus and renal involvement in chronic viral liver disease. J Med Life (2015) 0.75
Sequencing and Phylogenetic Study of Partial NS3 Gene of Iranian GB Virus C/Hepatitis G Virus (HGV) Originated From Hemodialysis Patients in Tehran. Hepat Mon (2015) 0.75
The Association Between Viral Infections and Co-stimulatory Gene Polymorphisms in Kidney Transplant Outcomes. Jundishapur J Microbiol (2016) 0.75
Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment. Antimicrob Agents Chemother (2014) 0.75
Systemic manifestations of hepatitis C infection. Infect Agent Cancer (2016) 0.75
Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon. CEN Case Rep (2014) 0.75
End-stage renal disease and African American race are independent predictors of mild liver fibrosis in patients with chronic hepatitis C infection. J Viral Hepat (2012) 0.75
Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol (2006) 0.75
The extrahepatic consequences of cirrhosis. MedGenMed (2006) 0.75
Association of aspartate aminotransferase with mortality in hemodialysis patients. Nephrol Dial Transplant (2015) 0.75
Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS). Dig Dis Sci (2016) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med (2005) 4.57
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Acute liver failure: Summary of a workshop. Hepatology (2008) 3.49
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr (2006) 3.32
Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol (2004) 2.82
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Optimal therapy of hepatitis C. Hepatology (2002) 2.40
Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int (2004) 2.37
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Elevated risk of stroke among patients with end-stage renal disease. Kidney Int (2003) 2.35
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology (2002) 2.19
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Cystatin C and subclinical brain infarction. J Am Soc Nephrol (2005) 1.88
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology (2007) 1.81
A framework for management of hepatitis C in prisons. Ann Intern Med (2006) 1.80
Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis (2003) 1.76
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology (2010) 1.67
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis (2013) 1.61
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol (2003) 1.57
Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol (2002) 1.57
Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis (2004) 1.54
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol (2010) 1.50
Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int (2003) 1.46
Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology (2010) 1.43
Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med (2005) 1.43
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Primary sclerosing cholangitis: summary of a workshop. Hepatology (2006) 1.38
Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med (2004) 1.36
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int (2002) 1.29
Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease. Kidney Int (2002) 1.27
Living donor liver transplantation: summary of a conference at The National Institutes of Health. Liver Transpl (2002) 1.22
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 1.19
LiverTox: a website on drug-induced liver injury. Hepatology (2013) 1.16
Cellular immune responses to the hepatitis B virus polymerase. J Immunol (2004) 1.15
Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol (2010) 1.14
Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology (2004) 1.12
Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology (2009) 1.12
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology (2008) 1.11
Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology (2007) 1.10
Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology (2006) 1.08
Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology (2008) 1.06
Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. Clin J Am Soc Nephrol (2008) 1.04
Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem (2003) 1.04
S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology (2010) 1.03
Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol (2009) 1.02
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol (2008) 1.00
Cardiovascular and thromboembolic events following hypertensive pregnancy. Am J Kidney Dis (2003) 0.99
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology (2006) 0.99
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Hepatitis B--preventable and now treatable. N Engl J Med (2006) 0.96
Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol (2006) 0.96
A step forward in therapy for hepatitis C. N Engl J Med (2009) 0.95
Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol (2012) 0.95
Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism (2003) 0.94
Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2012) 0.94
Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review. Antivir Ther (2007) 0.93
Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf (2014) 0.91
New therapies for hepatitis C. Hepatology (2007) 0.90
Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology (2009) 0.89
Evaluation of the patient with hepatitis B. Hepatology (2009) 0.88
Pilot study of interferon gamma for chronic hepatitis C. J Hepatol (2005) 0.88
Important factors in reliable determination of hepatitis C virus genotype by use of the 5' untranslated region. J Clin Microbiol (2013) 0.87
Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med (2012) 0.87
Viral kinetics in hepatitis C. Hepatology (2003) 0.86